Hyperuricemia is an independent predictive factor for left ventricular diastolic dysfunction in patients with chronic kidney disease.
BACKGROUND
It has been reported that elevated serum uric acid (UA) levels is an independent factor of poor prognosis in patients with chronic heart failure and chronic kidney disease (CKD).


OBJECTIVE
In our study, we assessed the potential impact of hyperuricemia on left ventricular (LV) diastolic dysfunction (DD) in patient with CKD.


METHODS
The study group consisted of 50 patients with CKD, stages 2-5. Standard echocardiography and tissue Doppler imaging (TDI) were performed. The levels of UA and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined. Patients were divided into two groups according to the results of peak mitral annular early diastolic velocity (EmLV): group with LV diastolic dysfunction (EmLV < 8 cm/s) DD (+) and group with normal LV diastolic function DD (-), when EmLV ≥ 8 cm/s.


RESULTS
Patients DD (+) group, as compared to DD (-) patients were characterized by significantly higher serum UA levels [6.7 (4.4-14.3) mg/dL vs 5.8 (1.9-8.9) mg/dL, p = 0.004] respectively. The area under the receiver operating characteristic (ROC) curve was of serum UA levels for the detection of LV diastolic dysfunction was 0.734, 95% confidence interval (CI) 0.590-0.849, p = 0.001, whereas ROC derived UA value of > 6.0 mg/dL was characterized by a sensitivity of 76.9% and specificity of 62.5% for diagnosing LV diastolic dysfunction. The independent variable predicting LV diastolic dysfunction as measured by a multivariate logistic regression analysis was UA level > 6.0 mg/dL with odds ratio (OR) = 14.3 (95% CI 2.0-103.2), p = 0.006.


CONCLUSIONS
Hyperuricemia is an independent predictive factor for LV diastolic dysfunction in patients with CKD.
Department of Internal Diseases, Gastroenterology and Hepatology, University Clinical Hospital in Olsztyn, Poland.
Leszek
L
Gromadziński
Department of Internal Diseases, Gastroenterology, Cardiology and Infectiology, University of Warmia and Mazury in Olsztyn, Poland.
Beata
B
Januszko-Giergielewicz
Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland.
Piotr
P
Pruszczyk
D000368:Aged; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D001783:Blood Flow Velocity; D003971:Diastole; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging / Q000473:pathology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D011379:Prognosis; D012372:ROC Curve; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging / Q000473:pathology; D012720:Severity of Illness Index; D014463:Ultrasonography; D014527:Uric Acid / Q000097:blood*; D018487:Ventricular Dysfunction, Left / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging / Q000473:pathology
D015415:Biomarkers; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D014527:Uric Acid